

Nrf2 activator (DMF) Ameliorated Oxidative Stress and Inflammation During H. Pylori Infection

Saif M. Hassan¹, Najah R. Hadi², Bassim I Mohammed³, and Mahmood J. Jawad¹

¹Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq, saif@g.alzahu.edu.iq, mahmood@g.alzahu.edu.iq

²Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Iraq, drnajahhadi@yahoo.com

³Department of Pharmacology, Faculty of pharmacy, University of Al-Qadisiya, Iraq, jumabassim@yahoo.co.uk

Abstract— Introduction: *Peptic ulcer disease is an illness that caused by an infection or long-term usage of stomach irritants such as medicines might cause it. H. Pylori cause gastric cell damage and may be death through generation of oxidative stress and an inflammation within the mucosal layer. It should be checked in all patients with peptic ulcers.*

Methods: *The information on the protective effect of pharmacological Nrf2 activator, e.g. DMF, in the treatment of peptic ulcer was obtained from Electronic databases accessed included Google Scholar, PubMed, Web of Science, and Scopus.*

Results: *H. pylori cause damage to gastric cell via ROS generation and enhance inflammatory cytokines. Nrf2 is a transcription factor that induce anti-oxidative stress enzymes and inhibit NF-κB, thereby, pharmacological activation of Nrf2 could reduce the effect of the pathogen and may be prevent damage or cell death.*

Conclusion: *DMF is a Nrf2 activator can be use in clinical trial to H. pylori induce gastric cells damage.*

Index Terms: DMF, H. pylori, Nrf2 activators, NF-κB, and ROS.

I. INTRODUCTION

In the current period, peptic ulcer disease is one of the most frequent chronic gastrointestinal disorders. It is now a prevalent global health concern that affects a vast number of people all over the world (1). Peptic ulcer disease (PUD) is a multifactorial and complicated condition characterized by stomach and duodenal ulcers. A peptic ulcer is a breach in the mucosa lining the stomach or proximal intestine that extends through the muscularis mucosae that arises in areas exposed to acid and pepsin. Peptic ulcer disease is a chronic, recurring condition characterized by poor wound healing. NSAIDs (nonsteroidal anti-inflammatory medications) are commonly used to treat pain, fever, inflammation, and rheumatic disease. Chronic use of these medications can result in a variety of gastrointestinal side effects, including gastric erosions, gastric or duodenal ulcers, and serious consequences include gastrointestinal hemorrhage and perforation. Induced by NSAIDs such as aspirin and indomethacin (2, 3). Stress plays an important role in pathophysiology of gastroduodenal ulceration due to reduced mucus production and enhanced acid secretion (4).

Other factor lead to ulceration is Smoking via impair healing and increase rate of ulcer recurrence. Cigarette smoking also increases the chance of getting an ulcer (5). Caffeine boosts stomach acid output, which can worsen an ulcer. Though there is no evidence of a link between alcohol use and peptic ulcers, ulcers are common in patients who have liver cirrhosis, a disease connected to high alcohol consumption. The amount of salt consumed in the diet was linked to the development of stomach ulcers (6). *Helicobacter pylori*, a gram-negative rod, is one of the most common causes of gastritis and the subsequent development of gastric and duodenal ulcers. *H. pylori* causes gastroduodenal diseases, which are associated with neutrophil, lymphocyte, monocyte, and plasma cell infiltration of the gastric mucosa (7). High oxidative stress induced with *H. pylori* infection is a significant factor. The production of pro-inflammatory cytokines, particularly interleukine-8, is made through a process (IL-8). IL-8 activated neutrophils, basophils, and T cells, attracting cells to the infection site. This promotes oxidative stress-induced stomach injury by generating high levels of ROS at the mucosa (8).

A. Reactive Oxygen Species

In the presence of chloride ions, myeloperoxidase causes production of the strong oxidant in neutrophils. Excessive ROS generation causes oxidative stress in the stomach mucosa, potentially causing damage to cellular components such as polyunsaturated fatty acids, proteins, and DNA. (9). When the energy was decrease in gastric cells caused by *H. pylori* decreases the rate of intracellular GSH re-generation. These findings suggest that decreased GSH levels after *H. pylori* colonization (10). lower GSH levels in the stomach mucosa may be linked to gastric carcinogenesis due to increase oxidation of DNA (11). Figure (1). As a result, medicinal drugs that suppress or scavenge ROS could be useful in the treatment of *H. pylori*-related stomach mucosal.

B. Gastric Inflammation

H. pylori leads to significant increases in steady-state mRNA levels and cell surface expression of ICAM-1 (12). *H. pylori* protein that promotes neutrophil adherence to endothelial

cells through the *H. pylori* neutrophil-activating protein (HP-NAP). HP-NAP activates neutrophil NADPH oxidase by binding to a particular receptor that is connected to a pertussin toxin-sensitive trimetric G protein (13). *H. pylori* infection activates NF- κ B and causes translocation, as well as elevated IL-8 levels, all of which are consistent with NF- κ B upregulation. NF- κ B activation can also control cellular growth responses, such as apoptosis. *H. pylori* can also emit TNF- α , therefore NF- κ B activation by *H. pylori* is a possibility (14). The production of ROS such as O₂, H₂O₂, and OH⁻, as well as peroxidation of membrane phospholipids such as malondialdehyde (MDA), can induce cellular harm by disrupting membrane phospholipids and mitochondrial respiration, resulting in DNA damage and malfunction. Furthermore, ROS can activate other mediators including inflammatory factors such as tumor necrosis factor (TNF-), myocytes chemoattractant protein-1 (MCP-1), IL-1, IL-6, and others (15, 16). Figure (1)




Fig. 1. A schematic diagram showing the pathogenesis *Helicobacter pylori* via enhance ROS generation and NF- κ B of the mucosal cell.

C. Pharmacological treatment

pharmacological therapy of PU is still evolving, with the goal of focusing on relief of pain, healing of ulcer, and prevention it recurrent. However, many of the pharmaceutical treatments for PU are designed to either counteract hostile influences or stimulate mucosal defense. Such medications are available. Antacids, histamine H₂-receptor antagonists, and other drugs (Table 1) are used to inhibit or neutralize stomach acid secretion.

Table 1: the drugs commonly used in management of PU.

Drug		M. A.	A. E.	R.
Proton Pump Inhibitors (PPIs)	Omeprazole Lansoprazole Rabeprazole	H ⁺ /K ⁺ -ATPase Inhibitor	Diarrhea N&V Constipation Flatulence B12 deficiency ↓ bone Ca	(17)
H ₂ -Blockers	Cimetidine Famotidine Ranitidine	Histamine H ₂ R Blocker	CNS depresses ↓ platelet coun.	(18)

Anti-acids	Al- OH Mg-OH	↑gastric pH	Frequency not defined: Nausea Vomiting Hypophosphatemia Chalky taste Constipation Abdominal cramping Diarrhea Electrolyte imbalance	(19)
Cytoprotective Agents	Misoprostol Sucralfate	Stimulate mucus production and enhance blood flow throughout the lining of the gastrointestinal tract	Nasopharyngitis Fall Contusion Diarrhea Upper respiratory tract inflammation Constipation Back pain Diarrhea Abdominal pain Headache Constipation	(20)

D. Herbal products

plant-derived items utilized in traditional around in the entire globe for the treatment of a wide range of maladies and diseases since ancient times. In the management and treatment of PU, herbal medicine is increasingly becoming a viable alternative to commercially available synthetic medicines (21). Strategies used by medicinal plants and their constituents for cytoprotectant are shown in figure 2. Some of the plants and their phytoconstituents showing antiulcer activity and their mechanism of cytoprotectant are tabulated in Table 2.




Fig. 2. Strategies used by medicinal plants and their constituents for cytoprotectant.

Table 2: medicinal plants and their mechanism of gastroprotectant.

Botanical name	Family	Plant extract used	Mechanism of Gastroprotection	Reference
Jasminum grandiflora	Oleaceae	70% ethanolic extract of leaves	Antisecretory, antioxidant, promote gastric healing, cytoprotective	(22)
Ocimum sanctum	Labiatae	ethanolic extract of leaves	Antisecretory, increase mucus production, cytoprotective	(23)
Urtica salicifolia	Periplocaceae	50% ethanolic extract of rhizome	Antioxidant, increase mucus production, cytoprotective	(24)
Amomum subulatum	Zingiberaceae	Methanolic extract of fruit	Increase mucus production, cytoprotective	(25)
Rhizophora mangle	rhizophoraceae	Aqueous extract of bark	Antioxidant, cytoprotective	(26)
Aegle marmelos	Rutaceae	Methanolic extract of fruit	Antioxidant, anti-inflammatory, promote gastric healing, cytoprotective	(27)
Calophyllum brasiliense	Calophyllaceae	Hexane extract of stem bark	Antisecretory, increase mucus production, cytoprotective	(28)
Anacardium occidentale	Anacardiaceae	70% ethanolic extract of leaves	Cytoprotective	(29)
Centella asiatica	Apiaceae	Aqueous extract of leaves	Antioxidant, cytoprotective	(1)
Nerium indicum	Apocynaceae	Methanolic extract of leaves	Antisecretory, cytoprotective	(30)

Nrf2

Nrf2 is a member of the CNC family termed erythroid-cell-derived-protein with CNC-homology (ECH), and it is divided into seven domains named Nrf2–ECH-homology (Neh) domains Neh-1 to Neh-7. Those cysteine residues can be changed in stressful situations, causing Nrf2 to be released from DLG motif side and remain attached to the ETGE motif side, allowing Nrf2 to translocate to the nucleus (31). Nrf2 forms a dimerization complex with the musculo-apo-neurotic-fibro-sarcoma (Maf) protein in the nucleus, which has facilitated Nrf2's binding to anti-response elements (AREs) within regulatory regions to activate a wide range of enzymes. These enzymes include NQO-1, SOD1, and HO-1, which work through oxidation-reduction reactions, nucleophile attack mechanisms, toxic metabolite efflux transporters, and thiol-containing compounds to maintain reduced conditions (32). The most prominent signaling that activates cellular defense systems against oxidative stress and electrophiles is the

transcription factor Nrf2 (31). Keap1 forms a cytoplasmic complex with Nrf2 under non-stress conditions, involving the Kelch domain of Keap1 and the ETGE and DLG motifs on Nrf2's Neh-2 domain (15). In stressful conditions, the Keap1 molecule, can be changed, causing Nrf2 to be released from the DLG motif side and remain connected to the ETGE motif side, allowing Nrf2 to translocate to the nucleus (33). Figure (3)




Fig. 3. Nrf2 activation mechanism (15).

II. AIM

Nrf2 activators have a role in the treatment peptic ulcer with H. Pylori positive patients.

III. DATA COLLECTIONS

The information on the protective effect of pharmacological Nrf2 activator, e.g. DMF, in the treatment of peptic ulcer was obtained from published peer-reviewed articles. Electronic databases accessed included Google Scholar, PubMed, Web of Science, and Scopus. All the articles obtained were reviewed to get the needed information on the activator used for the protective effect against H-pylori induce peptic ulcers.

IV. RESULTS

A. Anti-oxidant role of Nrf2

NQO1, HO-1, SODs, Grx1, and Trx1 are among the anti-oxidant enzymes and proteins produced when Nrf2 is activated. Oxygen free radicals were removed by SODs through converted it to H_2O_2 ; however, GSH systems were eliminated the latter (34). By acting as an electron donor for the reduction of peroxides, glutathione (GSH) detoxifies ROS such as superoxide and hydroxyl radicals. GSH synthesis is under the control of two enzymes which are γ -glutamylcysteine ligase and glutathione synthetase(35). NQO1 catalyzes the reduction and detoxification of quinones, as well as acting as an oxygen scavenger (36). Figure 4




Fig. 4. mechanism of Nrf2 activation antioxidant enzymes.

B. Anti-Inflammatory role of Nrf2

Inflammatory cells produce cytokines and chemokines in response to oxidative stress (37). The first and only inflammatory pathway triggered by oxidative stress and excessive cytokines and chemokines is NF- κ B. This overproduction stimulates ICAM-1 synthesis in leukocytes and vascular endothelium, as well as its ligand integrin, which leads to leukocyte migration into subendothelial tissues (38). Nrf2 inhibits NF- κ B activity by ubiquitinating IKK and inducing gene transcription (39). On another hand, The anti-oxidant genes are activated, which inhibit the of inflammatory markers production including TNF- α , IL-6, MCP-1, and MIP2, as well as the reduce level of VCAM-1, adhesion molecules and selectins (40). Figure (5)




Fig. 5. mechanism of Nrf2 induce anti-inflammatory substances and suppress of proinflammatory one

C. Dimethyl Fumarate (DMF)

DMF is an anti-oxidant and anti-inflammatory drug that activates the Nrf2 pathway while inhibiting the NF- κ B pathway. In addition to the glutathione system being modulated and the cellular response to O.S (41). Nrf2 interacts to Keap1 in the absence of DMF, causing it to be ubiquitinated. DMF disturbs the Keap1-Nrf2 complex at cysteine residues, causing Nrf2 to be free and translocated to the nucleus. Additionally, it inhibits the nuclear factor kappa-B pathway by binding to and activating the IKK at Cys-179. This binding prevents NF- κ B from being released from its cytoplasmic complex (NF- κ B-IB), hence suppressing downstream pro-inflammatory signaling pathways (15).

We hypothesize that DMF is an important medicine that can

minimize H. Pylori pathogenesis by reducing oxidative stress and inflammation, causing gastric ulcers by triggering anti-oxidant enzymes, inhibiting the NF- κ B pathway, and inhibiting both apoptotic proteins and TLR gene expression.

CONCLUSION

H. Pylori infection is the most important factor that effect on gastric cell integrity due to its toxic products such as ROS that destroy the cell wall and DNA as well as induction of inflammatory processes via enhance expression of NF- κ B. DMF, Nrf2 activator, has potential role in ameliorated oxidative stress via enhance induction of anti-oxidant genes and also inhibit activation of NF- κ B induce inflammatory mediators. So, we concluded that DMF play a role in protection of gastric cells against H. Pylori infection.

REFERENCES

1. Abdulla M, Al-Bayaty F, Younis L, Hassan MA. Anti-ulcer activity of Centella asiatica leaf extract against ethanol-induced gastric mucosal injury in rats. *Journal of medicinal plants research*. 2010;4(13):1253-9.
2. Konturek S, Obtulowicz W, Kwiecien N, Oleksy J. Generation of prostaglandins in gastric mucosa of patients with peptic ulcer disease: effect of nonsteroidal antiinflammatory compounds. *Scandinavian Journal of gastroenterology Supplement*. 1984;101:75-7.
3. Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. *World Journal of Gastroenterology: WJG*. 2005;11(26):4052.
4. Piper D, Greig M, Shinnors J, Thomas J, Crawford J. Chronic gastric ulcer and stress. *Digestion*. 1978;18(5-6):303-9.
5. Walker V, Taylor W. Cigarette smoking, chronic peptic ulceration, and pepsin 1 secretion. *Gut*. 1979;20(11):971-6.
6. Duggan JM, Duggan AE. The possible causes of the pandemic of peptic ulcer in the late 19th and early 20th century. *Medical journal of Australia*. 2006;185(11-12):667-9.
7. Gööz M, Gööz P, Smolka AJ. Epithelial and bacterial metalloproteinases and their inhibitors in H. pylori infection of human gastric cells. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 2001;281(3):G823-G32.
8. Remick DG. Interleukin-8. *Crit Care Med*. 2005;33(12 Suppl):S466-7.
9. Zhang X, Jiang A, Qi B, Ma Z, Xiong Y, Dou J, et al. Resveratrol Protects against Helicobacter pylori-Associated Gastritis by Combating Oxidative Stress. *Int J Mol Sci*. 2015;16(11):27757-69.
10. Park DK, Jeong SK, Chung MG, Kwon OS, Kim SS, Koo YS, et al. [Glutathione levels in Helicobacter pylori-infected gastric mucosa]. *Korean J Gastroenterol*. 2003;42(4):267-73.
11. Shi LQ, Zheng RL. DNA damage and oxidative stress induced by Helicobacter pylori in gastric epithelial cells: protection by vitamin C and sodium selenite. *Pharmazie*. 2006;61(7):631-7.
12. Kim H. Oxidative stress in Helicobacter pylori-induced gastric cell injury. *Inflammopharmacology*. 2005;13(1-3):63-74.
13. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. *J Exp Med*. 2000;191(9):1467-76.

14. Olivares D, Gisbert JP, Pajares JM. Helicobacter pylori infection and gastric mucosal epithelial cell apoptosis. *Rev Esp Enferm Dig.* 2005;97(7):505-20.
15. Hadi NR, Hassan SM, Jawad MJ, Alawaida W. Cerebral Ischemia Reperfusion Injury. *Cerebral Ischemia Reperfusion Injury.* 2021;1-63.
16. Hassan SM, Abbas AN, Mohammed MH, Fatima G, Singh RB, Singh J, et al. Role of arbs and aceis in the treatment of sars-cov2. *European Journal of Molecular and Clinical Medicine.* 2020;7(10):887-93.
17. Tian Y-Y, Jiang B, An L-J, Bao Y-M. Neuroprotective effect of catalpol against MPP+-induced oxidative stress in mesencephalic neurons. *European journal of pharmacology.* 2007;568(1-3):142-8.
18. Pension J, Wormsley K. Adverse reactions and interactions with H2-receptor antagonists. *Medical Toxicology.* 1986;1(3):192-216.
19. Patel D, Bertz R, Ren S, Boulton DW, Nâgård M. A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. *Clinical pharmacokinetics.* 2020;59(4):447-62.
20. Aubert J, Bejan-Angoulvant T, Jonville-Bera A. Pharmacology of misoprostol (pharmacokinetic data, adverse effects and teratogenic effects). *Journal de gynécologie, obstétrique et biologie de la reproduction.* 2014;43(2):114-22.
21. Hamed S, Arian AA, Farzaei MH. Gastroprotective effect of aqueous stem bark extract of Ziziphus jujuba L. against HCl/ethanol-induced gastric mucosal injury in rats. *Journal of traditional Chinese medicine.* 2015;35(6):666-70.
22. Umamaheswari M, Asokkumar K, Rathidevi R, Sivashanmugam A, Subhadradevi V, Ravi T. Antiulcer and in vitro antioxidant activities of Jasminum grandiflorum L. *Journal of ethnopharmacology.* 2007;110(3):464-70.
23. Sen S, Chakraborty R, De B, Mazumder J. Plants and phytochemicals for peptic ulcer: An overview. *Pharmacognosy Reviews.* 2009;3(6):270.
24. Rao CV, Ojha S, Radhakrishnan K, Govindarajan R, Rastogi S, Mehrotra S, et al. Antiulcer activity of Uleria salicifolia rhizome extract. *Journal of Ethnopharmacology.* 2004;91(2-3):243-9.
25. Rainsford K. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice. *Agents and Actions.* 1987;21(3):316-9.
26. Aguwa C, Nwako S. Preliminary studies of the root extracts of Nauclea latifolia Smith, for anti-ulcer properties. *Niger J Pharm Sci.* 1988;4:16-23.
27. Gautam M, Ghatule R, Singh A, Purohit V, Gangwar M, Kumar M, et al. Healing effects of Aegle marmelos (L.) Correa fruit extract on experimental colitis. 2013.
28. Garg G, Cho C, Ogle C. The role of the gastric mucosal sulphydryls in the ulcer-protecting effects of sulphasalazine. *Journal of pharmacy and pharmacology.* 1991;43(10):733-4.
29. Evans D. Extracts of Indian plants as mosquito larvicides. *Ind J Med Res.* 1988;88:38-41.
30. Govind P, Satish N, Shobhit S. Antiulcer activity of methanolic leaves extract of Nerium indicum Mill. *Int J Biomed Res.* 2010;1:55-61.
31. Al-Mudhaffer RH, Al-Huseini LMA, Hassan SM, Hadi NR. Bardoxolone Ameliorates Cerebral Ischemia/Reperfusion Injury in Male Rats. *Annals of Tropical Medicine and Public Health.* 2019;22:122-30.
32. Al-Huseini LMA, Al-Mudhaffer RH, Hassan SM, Hadi NR. DMF Ameliorating Cerebral Ischemia/Reperfusion Injury in Male Rats. *Systematic Reviews in Pharmacy.* 2019;10(1):206-13.
33. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. *J Biol Chem.* 2006;281(34):24756-68.
34. Flohé L, Toppo S, Cozza G, Ursini F. A comparison of thiol peroxidase mechanisms. *Antioxidants & redox signaling.* 2011;15(3):763-80.
35. Rahman I, Antonicelli F, MacNee W. Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells. *J Biol Chem.* 1999;274(8):5088-96.
36. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, et al. NAD (P) H: quinone oxidoreductase 1: role as a superoxide scavenger. *Molecular pharmacology.* 2004;65(5):1238-47.
37. Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. *Nature communications.* 2016;7:11624.
38. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF- α -activated vascular endothelium under flow. *Blood.* 2005;106(2):584-92.
39. Liu G-H, Qu J, Shen X. NF- κ B/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.* 2008;1783(5):713-27.
40. Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. *The Journal of Immunology.* 2004;172(6):3553-63.
41. Al-Mudhafer R, Abbas Al-Huseini L, Hassan S, Hadi N. Bardoxolone Ameliorates Cerebral Ischemia/ Reperfusion Injury in Male Rats. *Africa Health Research Organization.* 2019;22:122-30.